MYO Key Statistics, Chart & Performance
The current stock price of MYO is 1.08 USD. In the past month the price increased by 25.88%. In the past year, price decreased by -82.91%.
MYO Latest News, Press Relases and Analysis
MYO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 24.71 | 214.37B | ||
| ISRG | INTUITIVE SURGICAL INC | 63.57 | 194.04B | ||
| BSX | BOSTON SCIENTIFIC CORP | 31.1 | 136.01B | ||
| SYK | STRYKER CORP | 26.8 | 134.98B | ||
| BDX | BECTON DICKINSON AND CO | 13.9 | 57.21B | ||
| IDXX | IDEXX LABORATORIES INC | 56.11 | 56.49B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.78 | 48.88B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 18.75 | 39.20B | ||
| RMD | RESMED INC | 25.49 | 36.84B | ||
| DXCM | DEXCOM INC | 37.06 | 26.89B | ||
| PODD | INSULET CORP | 64.37 | 20.69B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.43 | 18.32B |
Related stock screener links
About MYO
Company Profile
Myomo, Inc. is a wearable medical robotics company, which engages in the business of developing, designing, and producing myoelectric orthotics for people with neuromuscular disorders. The company is headquartered in Boston, Massachusetts and currently employs 184 full-time employees. The company went IPO on 2017-06-12. The firm develops and markets the MyoPro product line, which is a myoelectric-controlled upper limb brace, or orthosis. MyoPro is a powered upper-limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury or other neuromuscular disease or injury. MyoPro senses a patient’s own electromyography (EMG) signals through non-invasive sensors on the arm and can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. MyoPro’s control technology utilizes an advanced human-machine interface based on non-invasive, patented electromyography, or EMG, control technology.
Company Info
MYOMO INC
137 Portland Street, 4th Floor
Boston MASSACHUSETTS 02114 US
CEO: Paul R. Gudonis
Employees: 185
Phone: 16179969058
MYOMO INC / MYO FAQ
What does MYO do?
Myomo, Inc. is a wearable medical robotics company, which engages in the business of developing, designing, and producing myoelectric orthotics for people with neuromuscular disorders. The company is headquartered in Boston, Massachusetts and currently employs 184 full-time employees. The company went IPO on 2017-06-12. The firm develops and markets the MyoPro product line, which is a myoelectric-controlled upper limb brace, or orthosis. MyoPro is a powered upper-limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury or other neuromuscular disease or injury. MyoPro senses a patient’s own electromyography (EMG) signals through non-invasive sensors on the arm and can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. MyoPro’s control technology utilizes an advanced human-machine interface based on non-invasive, patented electromyography, or EMG, control technology.
Can you provide the latest stock price for MYOMO INC?
The current stock price of MYO is 1.08 USD. The price increased by 0.93% in the last trading session.
What is the dividend status of MYOMO INC?
MYO does not pay a dividend.
What is the ChartMill technical and fundamental rating of MYO stock?
MYO has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the market cap for MYOMO INC?
MYOMO INC (MYO) has a market capitalization of 41.52M USD. This makes MYO a Nano Cap stock.
Who owns MYOMO INC?
You can find the ownership structure of MYOMO INC (MYO) on the Ownership tab.
MYO Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to MYO. When comparing the yearly performance of all stocks, MYO is a bad performer in the overall market: 89.33% of all stocks are doing better.
MYO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MYO. While MYO seems to be doing ok healthwise, there are quite some concerns on its profitability.
MYO Financial Highlights
Over the last trailing twelve months MYO reported a non-GAAP Earnings per Share(EPS) of -0.29. The EPS decreased by -26.09% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -24.11% | ||
| ROE | -52.93% | ||
| Debt/Equity | 0.22 |
MYO Forecast & Estimates
9 analysts have analysed MYO and the average price target is 5.1 USD. This implies a price increase of 372.22% is expected in the next year compared to the current price of 1.08.
For the next year, analysts expect an EPS growth of -117.45% and a revenue growth 32% for MYO